Regorafenib and wogonin eutectic and application thereof

A technology of wogonin and regorafenib, applied in the field of medicine, can solve the problems of low oral bioavailability, influence of absorption and treatment effect, etc., and achieve the effects of improving bioavailability, increasing solubility, and reducing tumor volume
CN111116462APending Publication Date: 2020-05-08QINGDAO CENT HOSPITAL
3 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
QINGDAO CENT HOSPITAL
Publication Date
2020-05-08

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a pharmaceutical composition for preventing and / or treating cancer and application thereof. The pharmaceutical composition takes regorafenib and wogonin as active ingredients,and the regorafenib and the wogonin exist in the form of eutectic. The compound disclosed by the invention has a good anti-cancer effect, particularly improves the solubility and bioavailability of an insoluble drug regorafenib for cocrystals of colon cancer, regorafenib and wogonin, and has a more remarkable anti-cancer effect compared with a physical mixture of the colon cancer, the regorafeniband wogonin.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of medical technology, in particular to a drug compound for treating cancer, especially colon cancer, the drug compound contains regorafenib and wogonin as active ingredients, both in the form of co-crystals exist. Background technique

[0002] Colon cancer is a common malignant tumor of the digestive tract that occurs in the colon, and it is more likely to occur at the junction of the rectum and the sigmoid colon. Tumor ranks third, and the incidence rate in my country is increasing year by year.

[0003] Regorafenib is an oral multikinase inhibitor that targets tumorigenesis, tumor angiogenesis and maintenance of the tumor microenvironment by inhibiting multiple protein kinases. In September 2012, the US Food and Drug Administration (FDA) approved it for the treatment of colorectal cancer, and it is an important targeted drug for the treatment of colon cancer. Regorafenib belongs to class II in the Biophar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More